FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W109232360> ?p ?o ?g. }

• W109232360 endingPage "3898" @default.
• W109232360 startingPage "3892" @default.
• W109232360 abstract "The CD-19-directed immunotoxin anti-B4-blocked ricin (anti-B4-bR) is currently in clinical trials for the treatment of B-cell malignancies. To explore the potential of using anti-B4-bR with chemotherapy protocols we tested the in vivo efficacy of the immunotoxin in combination with two multi-drug chemotherapeutic regimens in severe combined immunodeficient (SCID) mice bearing disseminated tumors of the multidrug-resistant human B-cell lymphoma Namalwa/mdr-1. In cytotoxicity studies in vitro, combinations of the immunotoxin with cisplatin produced supra-additive killing effects on both Namalwa and Namalwa/mdr-1 cells, whereas anti-B4-bR combined with 4-hydroperoxy- cyclophosphamide caused additive killing of both cell lines. In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwa/mdr-1 tumors. Treatment of Namalwa/mdr-1-bearing mice with anti-B4-bR alone or with the drug combination CHOE (consisting of cyclophosphamide, vincristine, doxorubicin, and etoposide) alone increased the lifespan of the tumor- burdened mice by 58% and 73%, respectively. However, treatment with five daily bolus intravenous injections of anti-B4-bR followed by CHOE increased the lifespan by 173%, and 20% of the mice were cured. The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwa/mdr-1 tumor-burdened mice by 129% compared with untreated controls. Combination therapy with anti-B4- bR and CCE produced long-term cures in 50% of the tumor-burdened mice. These results suggest that anti-B4-bR in combination with current multidrug regimens may constitute a highly efficacious modality for the treatment of drug-resistant B-cell malignancies." @default.
• W109232360 created "2016-06-24" @default.
• W109232360 creator A5005360775 @default.
• W109232360 creator A5010246449 @default.
• W109232360 creator A5036231578 @default.
• W109232360 creator A5040137655 @default.
• W109232360 creator A5046139499 @default.
• W109232360 date "1996-05-01" @default.
• W109232360 modified "2023-10-16" @default.
• W109232360 title "Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs" @default.
• W109232360 cites W13898768 @default.
• W109232360 cites W1487155761 @default.
• W109232360 cites W1487550059 @default.
• W109232360 cites W1489775606 @default.
• W109232360 cites W1491798957 @default.
• W109232360 cites W1499694712 @default.
• W109232360 cites W1545285984 @default.
• W109232360 cites W1548209838 @default.
• W109232360 cites W1548735291 @default.
• W109232360 cites W1637019120 @default.
• W109232360 cites W1754065147 @default.
• W109232360 cites W1812237374 @default.
• W109232360 cites W1844155670 @default.
• W109232360 cites W1859960333 @default.
• W109232360 cites W1997241897 @default.
• W109232360 cites W1998770834 @default.
• W109232360 cites W2019947202 @default.
• W109232360 cites W2049777761 @default.
• W109232360 cites W2063578373 @default.
• W109232360 cites W2072405957 @default.
• W109232360 cites W2096188315 @default.
• W109232360 cites W2107615796 @default.
• W109232360 cites W2121077184 @default.
• W109232360 cites W2136423026 @default.
• W109232360 cites W2138791276 @default.
• W109232360 cites W2143594378 @default.
• W109232360 cites W2158277472 @default.
• W109232360 cites W2206113074 @default.
• W109232360 cites W2228456847 @default.
• W109232360 cites W2267215445 @default.
• W109232360 cites W2279816465 @default.
• W109232360 cites W2305287298 @default.
• W109232360 cites W2318772898 @default.
• W109232360 cites W2334996101 @default.
• W109232360 cites W2404088503 @default.
• W109232360 cites W2415465271 @default.
• W109232360 cites W2424259720 @default.
• W109232360 cites W2469002193 @default.
• W109232360 cites W3024436806 @default.
• W109232360 cites W3146129082 @default.
• W109232360 cites W370878613 @default.
• W109232360 cites W85464595 @default.
• W109232360 cites W2045930276 @default.
• W109232360 doi "https://doi.org/10.1182/blood.v87.9.3892.bloodjournal8793892" @default.
• W109232360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8611717" @default.
• W109232360 hasPublicationYear "1996" @default.
• W109232360 type Work @default.
• W109232360 sameAs 109232360 @default.
• W109232360 citedByCount "25" @default.
• W109232360 countsByYear W1092323602012 @default.
• W109232360 countsByYear W1092323602013 @default.
• W109232360 countsByYear W1092323602015 @default.
• W109232360 crossrefType "journal-article" @default.
• W109232360 hasAuthorship W109232360A5005360775 @default.
• W109232360 hasAuthorship W109232360A5010246449 @default.
• W109232360 hasAuthorship W109232360A5036231578 @default.
• W109232360 hasAuthorship W109232360A5040137655 @default.
• W109232360 hasAuthorship W109232360A5046139499 @default.
• W109232360 hasBestOaLocation W1092323601 @default.
• W109232360 hasConcept C115085202 @default.
• W109232360 hasConcept C126322002 @default.
• W109232360 hasConcept C150903083 @default.
• W109232360 hasConcept C159654299 @default.
• W109232360 hasConcept C203014093 @default.
• W109232360 hasConcept C207001950 @default.
• W109232360 hasConcept C2776694085 @default.
• W109232360 hasConcept C2776755627 @default.
• W109232360 hasConcept C2778119113 @default.
• W109232360 hasConcept C2778239845 @default.
• W109232360 hasConcept C2779429289 @default.
• W109232360 hasConcept C2781303535 @default.
• W109232360 hasConcept C542903549 @default.
• W109232360 hasConcept C71924100 @default.
• W109232360 hasConcept C86803240 @default.
• W109232360 hasConcept C98274493 @default.
• W109232360 hasConceptScore W109232360C115085202 @default.
• W109232360 hasConceptScore W109232360C126322002 @default.
• W109232360 hasConceptScore W109232360C150903083 @default.
• W109232360 hasConceptScore W109232360C159654299 @default.
• W109232360 hasConceptScore W109232360C203014093 @default.
• W109232360 hasConceptScore W109232360C207001950 @default.
• W109232360 hasConceptScore W109232360C2776694085 @default.
• W109232360 hasConceptScore W109232360C2776755627 @default.
• W109232360 hasConceptScore W109232360C2778119113 @default.
• W109232360 hasConceptScore W109232360C2778239845 @default.
• W109232360 hasConceptScore W109232360C2779429289 @default.
• W109232360 hasConceptScore W109232360C2781303535 @default.
• W109232360 hasConceptScore W109232360C542903549 @default.

• next